←
dough83,722 posts
dough avatar

dough

@semodough

BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me

◷ Joined September 2015▧ 11,331 Photos and videos
dough avatar
dough@semodough·15 Oct 2019

Wonderful Day for me. - celebrating 25 GREAT years with my WIFE & best friend today. Best decision I ever made - happy #anniversary to my WIFE ❤️❤️

Post attachment
dough@semodough14 Oct 2017

Tomorrow 23 year anniversary +8 years of dating -like @SheffStation I started young 😃 MY WIFE best #LONGTERM Decisions I ever made ❤️❤️❤️

dough avatar
dough@semodough·1h

$AZN Jefferies pointed to 12 positive clinical trial readouts representing approximately $10 billion in potential sales, alongside an increasingly diversified pipeline spanning respiratory diseases, cardiovascular treatments and rare diseases.

$AZN AstraZeneca gets Jefferies backing as broker sees $80 billion sales target within reach tinyurl.com/23rwb666 #AZN

Breaking911 avatar
⟳ dough retweeted
Breaking911@Breaking911·1h

Dallas police are searching for a burglary suspect who allegedly used a massive forklift to rip an ATM out of the ground outside a Bank of Texas and drive off with it.

1:04
dough avatar
dough@semodough·1h

$CRVS $SNY Cowen March 2026 Survey: Surveyed Physicians Predict Dupixent Will Remain Most Prescribed Biologic For Asthma In 5 Years

$CRVS This paper highlights a key limitation of current asthma biologics: persistent neutrophilic airway inflammation ⤵️ After 12 months of biologic therapy, neutrophilic patients had significantly weaker responses than eosinophilic/mixed-granulocytic patients, with NO significant lung-function improvement and persistent airway neutrophilia. Most interesting: 82.7% of the neutrophilic patients were still T2-high by conventional biomarkers. So despite biologics suppressing T2/eosinophilic biology they did not eliminate the neutrophilic component of their disease. That is directly relevant to $CRVS's planned Ph2 asthma strategy: enroll BOTH T2/eosinophilic and non-T2 patients and test whether #ITK inhibition, through effects on both #Th2 and #Th17 differentiation and upstream #ILC2, can address the broad spectrum of asthma biology. The paper clearly defines the unmet biological problem that the $CRVS #soquelitinib trial is designed to test.

dough avatar
dough@semodough·1h

$LLY $XBI #biotechs Innovation Day (Dec-7 Will there be deal announced that day ?? $LLY M&A this year

Post attachment

$VKTX #Obesityweek26 $VKTX held investor event- 3 KOLS dosing flexibility KEY - one KOL saying monthly dosing could become standard of care - another KOL talking about long half life advantages & just as good as $LLY tirzepatide with dosing advantages could become number one agent used in his practices

dough avatar
dough@semodough·2h

$AVR $MDT Piper analyst out on $MDT says wait a minute I can do better & hold my beer - lol they all ready including revenue from $AVR - not sure I ever seen that before buyout is official

$MDT - NEEDHAM basically calling out $MDT you need $AVR more then ever to compete ??🤷‍♂️ note that MDT has seen some pressure on its transcatheter aortic valve replacement (TAVR) business due to 6-7 year data from the Evolut Low Risk trial that showed a higher reintervention rate compared to surgery (5.5% vs. 3.3% at 6 years) which was driven by aortic regurgitation. Management noted that while this hurt US TAVR growth initially, they have seen procedure volumes stabilize. On our recent cardiology expert call, Dr. Andrew Goldsweig indicated that the market increasingly favors balloon-expandable TAVR designs and that Edwards Lifesciences' (EW - Not Covered) currently has the best TAVR and that MDT is at risk of market share loss until it launches its own balloon-expandable TAVR.

dough avatar
dough@semodough·5h

$VKTX @jefferies only matter time before we see 2735/3019 combo. Also mentioned 3019 multiple back up compounds with even longer half life’s

$VKTX BRiley PT$85 Viking’s amylin VK3019 posted 12.0% weight loss in 19 days of monkey dosing, nearly triple what its own lead drug VK2735 managed, and more than Lilly’s tirzepatide delivered in eight weeks. • Two backup molecules last twice as long, putting a once-monthly combination shot in play. • VK2735’s cholesterol and triglyceride gains survived the step down from weekly to monthly dosing. • First human VK3019 data hits in 4Q26, and at ~$2.4B EV, the market is paying almost nothing for the amylin franchise

dough avatar
dough@semodough·6h

$BBIO Jefferies BUY PT$110 2 different notes out - overall one & other why Attruby more potent then Tafamidis with early separation

$BBIO “SEPARATION IN FIRST MONTH - #Acoramidis is superior drug & should be used first #AHA

Post attachment
dough avatar
dough@semodough·6h

$MDT - NEEDHAM basically calling out $MDT you need $AVR more then ever to compete ??🤷‍♂️ note that MDT has seen some pressure on its transcatheter aortic valve replacement (TAVR) business due to 6-7 year data from the Evolut Low Risk trial that showed a higher reintervention rate compared to surgery (5.5% vs. 3.3% at 6 years) which was driven by aortic regurgitation. Management noted that while this hurt US TAVR growth initially, they have seen procedure volumes stabilize. On our recent cardiology expert call, Dr. Andrew Goldsweig indicated that the market increasingly favors balloon-expandable TAVR designs and that Edwards Lifesciences' (EW - Not Covered) currently has the best TAVR and that MDT is at risk of market share loss until it launches its own balloon-expandable TAVR.

dough avatar
dough@semodough·7h

$RYTM LR believe there is room for further stock upside as global launch execution builds confidence in the long-term aHO opportunity and peak sales potential. • Further, discussions with mgt & investors at Obesity Week suggest investor attention is gradually shifting toward the next growth drivers, particularly Prader-Willi syndrome (PWS) and next- generation MC4R agonists.

$RYTM good reminder just how cheap $VKTX is

dough avatar
dough@semodough·7h

$VKTX BRiley PT$85 Viking’s amylin VK3019 posted 12.0% weight loss in 19 days of monkey dosing, nearly triple what its own lead drug VK2735 managed, and more than Lilly’s tirzepatide delivered in eight weeks. • Two backup molecules last twice as long, putting a once-monthly combination shot in play. • VK2735’s cholesterol and triglyceride gains survived the step down from weekly to monthly dosing. • First human VK3019 data hits in 4Q26, and at ~$2.4B EV, the market is paying almost nothing for the amylin franchise

$VKTX

Post attachment
dough avatar
dough@semodough·7h

$DIS BofA ⬆️ $135

DISNEY $DIS Q4’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $25.95B (Est. $25.18B) 🟢; +16% YoY 🔹 Adj. EPS: $1.77 (Est. $1.67) 🟢; +59% YoY 🔹 Total Segment Oper Income: $4.97B (Est. $4.8B) 🟢; +43% YoY 🔹 FCF: $4.84B (Est. $4.46B) 🟢; +89% YoY Segment Oper Income: 🔹 Experiences: $2.25B; +20% YoY 🔹 Entertainment: $1.33B; +92% YoY 🔹 Sports: $1.39B; +53% YoY FY27 Guide: 🔹 Free Cash Flow: ~$11B (Est. $10.57B) 🟢 🔹 Adj. EPS Growth: Double-digit, ex-53rd week 🔹 Total Segment Oper Income Growth: ~8%, ex-53rd week 🔹 Share Repurchases: ~$9B 🔹 CapEx: ~$9B Q1 FY27 Guide: 🔹 Total Segment Oper Income: ~$5.4B Announcements: 🔹 Board declared a dividend of $2.00 per share, payable in two installments of $1.00 per share; a 33% increase over the $1.50 per share paid in fiscal 2026 Key Updates: 🔸 Q4 included one additional week of operations (the 53rd week), which added 33 ppts to Entertainment, 10 ppts to Experiences and 9 ppts to Sports segment operating income growth vs. the prior-year quarter, and approximately $0.17 to full-year adjusted EPS. 🔸 Excluding the 53rd week, fiscal 2026 total segment operating income grew approximately 10% and adjusted EPS grew 16%. Disney exceeded its fourth quarter total segment operating income and full year adjusted EPS guidance. 🔸 Fiscal 2027 guidance gives effect to reporting changes, including the exclusion of equity income from Entertainment segment operating results.

Post attachment